RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome

Launched by IRCCS POLICLINICO S. DONATO · Sep 25, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at how certain RNA molecules in the blood can help predict heart problems in patients who have experienced an acute coronary syndrome (ACS), which is a serious condition that affects blood flow to the heart. The goal is to find specific blood markers that can indicate whether a patient's heart function might decline after a procedure called percutaneous coronary intervention (PCI), which is a common treatment to open blocked arteries.

To participate in the study, patients must be at least 18 years old and experiencing their first episode of ACS, and they must be scheduled for PCI. However, certain conditions may prevent someone from joining, such as having severe heart valve issues or a history of heart surgery. Participants will be asked to give their consent to take part in the study, and they will be monitored to see how these RNA markers relate to their heart health following the procedure. This research could help doctors better understand heart risks and improve care for patients with similar conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age \>18 years
• • 2. Patients with ACS (first episode), defined according to the guidelines of the European Society of Cardiology (ESC) 2017
• • 3. Indication for percutaneous revascularization treatment
• • 4. Informed consent to study enrollment
• Exclusion Criteria:
• • 1. Severe valve disease or other conditions requiring cardiac surgery
• • 2. Previous cardiac surgery including coronary artery bypass grafts
• • 3. Total chronic occlusions
• 4. Patients with known hypersensitivity or contraindication to any of the following drugs:
• • heparin
• • aspirin,
• • clopidogrel,
• • ticlopidine,
• • sirolimus,
• • everolimus.
• • 5. Any contraindication to drug-eluting stent implantation (DES)
• • 6. Patients with a documented history of myocardial infarction;
• • 7. Left ventricular ejection fraction (LVEF) \<30% before PCI
• • 8. Patients in cardiogenic shock
• • 9. Patients with advanced ST-segment elevation myocardial infarction (\> 48 h from onset of symptoms/Q waves on electrocardiogram) or undergoing fibrinolysis;
• • 10. Patients with prior known cardiomyopathy with LVEF \< 40%
• • 11. Patients with malignant neoplasm or systemic disease with quoad vitam prognosis less than 1 year;
• • 12. Patients with known active infectious diseases;
• • 13. Patients who are unable to express valid informed consent to the act of enlistment
• • 14. Pregnant women